Please login to the form below

Not currently logged in

FDA approves Pfizer's bipolar treatment

The FDA has approved Pfizer's Geodon capsules as an adjunct to lithium or valproate as a maintenance treatment for bipolar I disorder in adults

The US Food and Drug Administration (FDA) has approved Pfizer's Geodon (ziprasidone HCI) capsules as an adjunct to lithium or valproate as a maintenance treatment for bipolar I disorder in adults.

Geodon's safety and efficacy were tested during a six-month, double-blind, randomised, placebo-controlled trial in adults with bipolar I disorder. Clinical data showed the drug to be effective as a well tolerated long-term treatment to control symptoms of bipolar disorder in adults.

During six months of treatment, 19.7 per cent of patients who received Geodon required intervention for a mood episode, compared with 32.4 per cent of patients who received the placebo.

"The recurrence of mood episodes associated with bipolar disorder can have a devastating impact on patients' lives," said Dr Ilise Lombardo, senior medical director, Pfizer Specialty Care. "This approval underscores Pfizer's commitment to supporting people suffering from serious mental health disorders."

Geodon is also approved in the US for the treatment of acute manic and mixed episodes associated with bipolar disorder, with or without psychotic features, and for the treatment of schizophrenia.

23rd November 2009


Featured jobs

Subscribe to our email news alerts


Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...